DE69627147T2 - Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung - Google Patents

Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung

Info

Publication number
DE69627147T2
DE69627147T2 DE69627147T DE69627147T DE69627147T2 DE 69627147 T2 DE69627147 T2 DE 69627147T2 DE 69627147 T DE69627147 T DE 69627147T DE 69627147 T DE69627147 T DE 69627147T DE 69627147 T2 DE69627147 T2 DE 69627147T2
Authority
DE
Germany
Prior art keywords
oral preparation
zonula occludens
occludens toxin
preparation contained
biologic active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69627147T
Other languages
English (en)
Other versions
DE69627147D1 (de
Inventor
Alessio Fasano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/443,864 external-priority patent/US5827534A/en
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of DE69627147D1 publication Critical patent/DE69627147D1/de
Application granted granted Critical
Publication of DE69627147T2 publication Critical patent/DE69627147T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69627147T 1995-05-24 1996-05-16 Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung Expired - Fee Related DE69627147T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/443,864 US5827534A (en) 1995-05-24 1995-05-24 Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US08/598,852 US5665389A (en) 1995-05-24 1996-02-09 Oral dosage composition for intestinal delivery and method of treating diabetes
PCT/US1996/006870 WO1996037196A1 (en) 1995-05-24 1996-05-16 Oral dosage composition for intestinal delivery and method of use of the same

Publications (2)

Publication Number Publication Date
DE69627147D1 DE69627147D1 (de) 2003-05-08
DE69627147T2 true DE69627147T2 (de) 2003-12-11

Family

ID=27033689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69627147T Expired - Fee Related DE69627147T2 (de) 1995-05-24 1996-05-16 Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung

Country Status (9)

Country Link
US (1) US5665389A (de)
EP (1) EP0828481B1 (de)
JP (2) JP3846901B2 (de)
AT (1) ATE235893T1 (de)
AU (1) AU702385B2 (de)
CA (1) CA2222018A1 (de)
DE (1) DE69627147T2 (de)
ES (1) ES2194989T3 (de)
WO (1) WO1996037196A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5912323A (en) * 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US5864014A (en) * 1997-02-20 1999-01-26 University Of Maryland At Baltimore Zonula occludens toxin receptor
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
ATE438405T1 (de) * 2000-05-19 2009-08-15 Univ Maryland Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US8383129B2 (en) 2003-01-10 2013-02-26 Centro De Investigacion Y De Estudios Avanzados Del Instituto Politecnico Nacional Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability
AU2004220544B2 (en) * 2003-03-06 2010-06-17 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US7286223B2 (en) * 2003-03-18 2007-10-23 Loma Linda University Medical Center Method and apparatus for detecting embedded rebar within an interaction region of a structure irradiated with laser light
US7294689B2 (en) * 2003-07-15 2007-11-13 University Of Maryland, Baltimore Agonist polypeptide of receptor for Zot and Zonulin
CA2614068A1 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
CA2575587C (en) * 2004-08-03 2014-06-17 Vital Health Sciences Pty Ltd Carrier for enteral administration
AR053661A1 (es) * 2005-01-14 2007-05-16 Univ Maryland Peptido para entregar vacunas via mucosas
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
WO2006133506A1 (en) 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
RU2008136208A (ru) * 2006-02-09 2010-03-20 Альба Терапьютикс Корпорейшн (Us) Композиции для эффектора плотных контактов
WO2009023311A2 (en) * 2007-05-07 2009-02-19 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
WO2009015382A2 (en) 2007-07-26 2009-01-29 Alba Therapeutics Corporation Novel peptides that enhance tight junction permeability
CA2734139C (en) 2007-10-02 2019-12-24 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (de) 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Herstellung von Peptiden und Reinigungsverfahren
EP2531047A4 (de) 2010-02-05 2014-03-19 Phosphagenics Ltd Träger mit einem nichtneutralisierten tocopherylphosphat
EP2552486B1 (de) 2010-03-30 2020-08-12 Phosphagenics Limited Pflaster für transdermale verabreichung
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
KR102236462B1 (ko) 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
CN103923216B (zh) * 2014-04-22 2016-04-27 吉林大学 多功能模块融合蛋白及其在提高蛋白质类药物口服生物利用度中的应用
WO2017096427A1 (en) 2015-12-09 2017-06-15 Phosphagenics Limited Pharmaceutical formulation
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
CN110891587A (zh) 2017-02-10 2020-03-17 创新生物制药有限公司 用于治疗与肠上皮通透性相关的疾病的组合物和方法

Also Published As

Publication number Publication date
DE69627147D1 (de) 2003-05-08
ATE235893T1 (de) 2003-04-15
AU702385B2 (en) 1999-02-18
JP2003155253A (ja) 2003-05-27
JP3846901B2 (ja) 2006-11-15
EP0828481A1 (de) 1998-03-18
EP0828481B1 (de) 2003-04-02
WO1996037196A1 (en) 1996-11-28
EP0828481A4 (de) 1999-06-09
US5665389A (en) 1997-09-09
ES2194989T3 (es) 2003-12-01
CA2222018A1 (en) 1996-11-28
JPH11505844A (ja) 1999-05-25
AU5792996A (en) 1996-12-11

Similar Documents

Publication Publication Date Title
DE69627147D1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
AU5906398A (en) Dosage composition for nasal delivery and method of use of the same
SE9504661D0 (sv) New compounds
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
BG101118A (en) Therapeutical compounds
GEP20053602B (en) Aripiprazole for Oral Administration
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
MX9709146A (es) Compuestos novedosos, preparacion y uso de los mismos.
PL325339A1 (en) Derivatives of piperasine as neurokinin antagonists
DE60019334D1 (de) Antivirale arznei
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
ATE234636T1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
DK0917460T3 (da) Cyclosporin-formulering
PT1066304E (pt) Antagonistas macrolidos de lhrh
SE9504662D0 (sv) New compounds
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
BG104827A (en) 3',3'-n-bis-substituted macrolide lhrh antagonists
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
MX9803694A (es) Derivados de 3-desoxi-3-desclandinosa de eritromicinas a y b.
CO4180553A1 (es) Composiciones para el tratamiento de la peridontitis adulta

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee